Living donor liver transplantation (LDLT) has emerged as a critical therapeutic modality in regions with limited deceased donor availability, particularly in Egypt, where liver disease burden remains high due to endemic hepatitis C virus (HCV) infection. Despite advancements in surgical techniques and perioperative care, infectious morbidity remains a leading cause of post-transplant complications, significantly influencing graft survival and patient outcomes. This systematic review and clinical outcome analysis evaluates risk stratification frameworks and infectious morbidity patterns in Egyptian LDLT settings, synthesizing evidence from published regional and international studies.

The review integrates epidemiological, clinical, and surgical literature to examine infection-related complications, postoperative immunological vulnerability, and healthcare system limitations. Findings indicate that infectious complications are multifactorial, influenced by recipient comorbidities, surgical complexity, perioperative immunosuppression, and healthcare infrastructure variability. Additionally, the transition toward improved transplantation systems in Egypt reflects evolving clinical practices but highlights persistent gaps in infection control and standardized risk assessment models.

This study underscores the need for structured predictive risk models tailored to Egyptian transplant populations, integrating metabolic, viral, and perioperative infection risk variables. Strengthening surveillance systems and refining immunosuppressive protocols are essential to improving post-LDLT outcomes.

Living donor liver transplantation, infectious morbidity, risk stratification

Abdellatif AA, Mogawer MS, El-Shazli M, El-Karaksy H, Salah A, Abdel-Maqsod A, et al. Resuming post living donor liver transplantation in the COVID-19 pandemic: real-life experience, single-center experience. Egypt Liver J. 2021;11(1):92. [PMID: 34956680, PMCID: PMC8686346]

Amer KE, Marwan I. Living donor liver transplantation in Egypt. Hepatobiliary Surg Nutr. 2016;5(2):98-106. [PMID: 27115003, PMCID: PMC4824739]

Chan SC, Fan ST. Historical perspective of living donor liver transplantation. World J Gastroenterol. 2008;14(1):15-21. [PMID: 18176956, PMCID: PMC2673383]

Cananzi M, Gaio P, Boscardin C, Pescarin M, Bosa L. In: Indications to Liver Transplantation in Children. Springer; 2022. p. 495-507. [PMCID: PMCID]

El-Karaksy H, El-Koofy N, El-Sayed R, El-Raziky M, Rabah F, El-Shabrawi M, et al. Limitations of Living Donor Liver Transplantation in Egyptian Children. Hepatogastroenterology. 2014;61(132):1090-3. [PMID: 26158170]

El-Meteini M, Montasser IF, El Gendy E, Dabbous H, Hashem RE, William P, et al. Assessment of health-related quality of life in Egyptian HCV-infected recipients after living donor liver transplantation. J Dig Dis. 2015;16(11):675-82. [PMID: 26469999]

Hafez MH. Road To Deceased Donor Transplantation in Egypt. Exp Clin Transplant. 2024;22(Suppl 4):33-6. [PMID: 38775695]

Khalaf H. Long-term outcome after liver transplantation in Egyptians transplanted for hepatitis C virus cirrhosis. Transplant Proc. 2003;35(7):2777-8. [PMID: 14612116]

Khalaf H, Marwan I, Al-Sebayel M, El-Meteini M, Hosny A, Abdel-Wahab M, et al. Status of liver transplantation in the Arab world. Transplantation. 2014;97(7):722-4. [PMID: 24603475]

Kamel R, Hatata Y, Hosny K, Amer K, Taha M. Synthetic graft for reconstruction of middle hepatic vein tributaries in living-donor liver transplant. Exp Clin Transplant. 2015;13 Suppl 1(Supplement 1):318-22. [PMID: 25894182]

Khalil Dabbous HM, El-Sayed EA, Abdel All NA. Risk Factors of Metabolic Syndrome among Post Living Donor Liver Transplant Egyptian Recipients: Single Center Study. QJM: An International Journal of Medicine. 2024;117(Supplement_1).

Mabrouk M, Esmat G, Yosry A, El-Serafy M, Doss W, Zayed N, et al. Health-related quality of life in Egyptian patients after liver transplantation. Ann Hepatol. 2012;11(6):882-90.

Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13(1):288. [PMID: 23799878, PMCID: PMC3702438]

Nassar M, Nso N, Lakhdar S, Kondaveeti R, Buttar C, Bhangoo H, et al. New onset hypertension after transplantation. World J Transplant. 2022;12(3):42-54. [PMID: 35433331, PMCID: PMC8968475]

Naylor KL, Kim SJ, Smith G, McArthur E, Kwong JC, Dixon SN, et al. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. Am J Transplant. 2022;22(9):2228-36. [PMID: 35578576, PMCID: PMC9347443]

Salah M, Dabbous HM, Montasser IF, Bahaa M, Abdou AMH, Elmeteini MS. Covid-19 in recipients of living donor liver transplantation: a worse or an equivalent outcome? QJM. 2022;115(2):69-76. [PMID: 34963013, PMCID: PMC9383128]

Starzl T, Marchioro T, von Kaulla K, Hermann G, Brittain R, Waddell W. homotransplantation of the liver in humans. surg. gynecol. obstet. 1963;522.

Strong R, Lynch S. Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med. 1990;322:1505-7.